XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rajabzadeh M, Khadem ansari M H, Khardmand F, Rasmi Y, Gholinejad Z. Serum levels of interleukin-10 and its receptor in the multiple myeloma type I patients. Journal of Research in Applied and Basic Medical Sciences 2023; 9 (4) :193-199
URL: http://ijrabms.umsu.ac.ir/article-1-266-en.html
Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran , mahdi.r7392@yahoo.com
Abstract:   (197 Views)
Background & Aims: Multiple myeloma is a malignancy of plasma cells that is associated with high morbidity rate. Inflammation is a common feature in malignancy and plays a pivotal role in the cancer pathogenesis. Interleukin-10 is a cytokine with anti-inflammatory properties. The aim of this study was evaluation the importance of interleukin-10 and its receptor in multiple myeloma in order to find their pathogenic roles and diagnostic value.
Materials & Methods: In this case-control study, 30 multiple myeloma patients and 40 healthy subjects were enrolled. Serum IL-10 and IL-10R1 levels were determined using ELISA method. Data analysis was performed by SPSS software version 23 including descriptive analysis, mean compression and correlation tests.
Results: The mean IL-10 levels were 50.93± 8.76 and 52.56 ± 10.47 pg/ml in control and patient groups, respectively. The serum IL-10R levels of multiple myeloma patients were significantly lower than healthy control (p=0.041) where mean serum levels were
2.51 ± 0.86 and 2.1± 0.76 pg/ml, respectively. We found a positive correlation between IL-10 and IL-10R levels (p = 0.042).

Conclusion: These results demonstrated that IL-10R but not IL-10 is increased in the patient's serum and they are proposed as a new diagnostic biomarker. In other words, downregulation of IL-10 receptor and attenuation of IL-10 bio-effect are associated with further inflammation in multiple myeloma type I patients.
Full-Text [PDF 483 kb]   (77 Downloads) |   |   Full-Text (HTML)  (30 Views)  
Type of Study: orginal article | Subject: Other

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7(8):585. [DOI:10.1038/nrc2189] [PMID]
2. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016;43(6):676-81. [DOI:10.1053/j.seminoncol.2016.11.004] [PMID] []
3. Harris NS, Winter WE. Multiple myeloma and related serum protein disorders: an electrophoretic guide: Demos Medical Publishing; 2012. [Google Book]
4. Schottelius AJ, Dinter H. Cytokines, NF-κB, microenvironment, intestinal inflammation and cancer. The Link Between Inflammation and Cancer: Springer; 2006. p. 67-87. [DOI:10.1007/0-387-26283-0_3] [PMID]
5. Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Nature Publishing Group; 2006. [DOI:10.1038/sj.leu.2404229] [PMID]
6. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97(10):2440-52. [DOI:10.1002/cncr.11072] [PMID]
7. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20(33):4519-27. [DOI:10.1038/sj.onc.1204623] [PMID]
8. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Netw 1999;10(1):65-70. [PMID]
9. Alexandrakis M, Passam F, Ganotakis E, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin‐6 (IL‐6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003;25(1):41-6. [DOI:10.1046/j.1365-2257.2003.00492.x] [PMID]
10. Kyrtsonis MC, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, et al. Soluble interleukin‐6 receptor (sIL‐6R), a new prognostic factor in multiple myeloma. Br J Haematol 1996;93(2):398-400. [DOI:10.1046/j.1365-2141.1996.4721018.x] [PMID]
11. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13(6):1117-25. [DOI:10.1016/S0889-8588(05)70115-5] [PMID]
12. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75(2):263-74. [DOI:10.1016/0092-8674(93)80068-P] [PMID]
13. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71-109. [DOI:10.1146/annurev-immunol-031210-101312] [PMID]
14. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kühn R, et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immun 1996;157(2):798-805. [DOI:10.4049/jimmunol.157.2.798] [PMID]
15. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66(11):5224-31. [DOI:10.1128/IAI.66.11.5224-5231.1998] [PMID] []
16. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant Janus kinase 2 activation. Blood 2012:blood-2011-10-388538. [DOI:10.1182/blood-2011-10-388538] [PMID] []
17. Liu Y, Wei S, Ho A, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immun 1994;152(4):1821-9. [DOI:10.4049/jimmunol.152.4.1821] [PMID]
18. Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Interleukin-10 in Health and Disease: Springer; 2014. p. 191-212. [DOI:10.1007/978-3-662-43492-5_9] [PMID] []
19. Boulland M-L, Meignin V, Leroy-Viard K, Copie-Bergman C, Brière J, Touitou R, et al. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Clin Pathol 1998;153(4):1229-37. [DOI:10.1016/S0002-9440(10)65667-2] [PMID]
20. Kyle RA, Steensma DP. History of multiple myeloma. Multiple Myeloma 2011:3-23. [DOI:10.1007/978-3-540-85772-3_1] [PMID]
21. Khadem-Ansari M-H, Faridvand Y, Oskuyi AE. Lipid profile assessment in stage I multiple myeloma. Clin Comm Oncol 2014;1(1):3. [DOI:10.4103/2393-8633.132176]
22. Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm 2017;2017:1852517. [DOI:10.1155/2017/1852517] [PMID] []
23. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, et al. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007;37(2):171-5. [DOI:10.1016/j.cyto.2007.02.022] [PMID]
24. Wang H, Wang L, Chi PD, Wang WD, Chen XQ, Geng QR, et al. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. Br J Cancer 2016;114(4):463-8. [DOI:10.1038/bjc.2016.11] [PMID] []
25. Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A Biol Sci Med Sci 2010;65(4):429-33. [DOI:10.1093/gerona/glp198] [PMID] []
26. Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist 2002;7(Supplement 1):20-9. [DOI:10.1634/theoncologist.7-suppl_1-20] [PMID]
27. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K, et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005;96(2):241-6. [DOI:10.1016/j.imlet.2004.08.015] [PMID]
28. Brody GH, Yu T, Miller GE, Chen E. Discrimination, racial identity, and cytokine levels among African-American adolescents. J Adolesc Health 2015;56(5):496-501. [DOI:10.1016/j.jadohealth.2015.01.017] [PMID] []
29. Attie AD, Raines RT. Analysis of Receptor-Ligand Interactions. J Chem Educ 1995;72(2):119-24. [DOI:10.1021/ed072p119] [PMID] []
30. Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, et al. The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One 2013;8(3):e58504. [DOI:10.1371/journal.pone.0058504] [PMID] []
31. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992a;6(2):273-84. [DOI:10.1016/S0889-8588(18)30344-7] [PMID]
32. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97(10):2440-52. [DOI:10.1002/cncr.11072] [PMID]
33. Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol 2014;380:191-212. [DOI:10.1007/978-3-662-43492-5_9] [PMID] []
34. Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, et al. Polymorphism of IL-10 receptor beta affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol 2017;35(4):711-8. [DOI:10.1002/hon.2322] [PMID]
35. Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Yawata Y, et al. Expression and production of interleukin 10 in human myeloma cell lines. Br J Haematol 2000;111(3):835-42. [DOI:10.1111/j.1365-2141.2000.02413.x] [PMID]
36. Urbanska-Rys H, Wiersbowska A, Stepien H, Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000;11(3):443-51. [Google Scholar]
37. Shekarriz R, Janbabaei G, Kenari SA. Prognostic value of IL-10 and its relationship with disease stage in Iranian patients with multiple myeloma. Asian Pac J Cancer Prev 2018;19(1):27. [PMID]
38. Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, Koh A, et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 2004;172(8):4733-43. [DOI:10.4049/jimmunol.172.8.4733] [PMID]
39. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Experim Med 2003;197(1):7-17. [DOI:10.1084/jem.20021229] [PMID] []
40. Quinn SR, O'Neill LA. The role of microRNAs in the control and mechanism of action of IL-10. Curr Top Microbiol Immunol 2014;380:145-55. [DOI:10.1007/978-3-662-43492-5_7] [PMID]
41. Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma. Cancers 2019;11(11):1738. [DOI:10.3390/cancers11111738] [PMID] []
42. Chong PSY, Chng WJ, de Mel S. STAT3: A Promising Therapeutic Target in Multiple Myeloma. Cancers 2019;11(5). [DOI:10.3390/cancers11050731] [PMID] []

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb